Gout News

Starting urate lowering therapy during a gout flare does not impact the flare’s severity, duration or risk for recurrence over the following month, according to a systematic review and meta-analysis.

SCOTTSDALE, Ariz. — Although many rheumatologists may not reach for biologic therapies for gout management, interleukin-1 and 6 inhibitors may have utility in managing mobilization flares, according to a speaker here.

Fatigue in patients with inflammatory rheumatic and musculoskeletal diseases should be addressed with tailored physical activity, psychoeducational interventions or possibly immunomodulatory treatment, according to EULAR recommendations.

Last November, at the American College of Rheumatology Convergence 2023, several faculty members presented new data on how a class of drugs used in type 2 diabetes may also be beneficial in patients with lupus and gout.

The FDA has approved an abbreviated new drug application for Lupin Limited’s generic febuxostat 40 mg and 80 mg tablets, according to a press release from the manufacturer.

The FDA has approved an abbreviated new drug application from ANI Pharmaceuticals for indomethacin oral suspension, a generic version of Indocin oral suspension, according to a press release from the manufacturer.

Poverty and chronic inflammation together may have a “synergistic” impact leading to higher all-cause mortality, including a 127% increased heart disease mortality risk and a 196% higher risk for cancer mortality, according to data.

SAN DIEGO — Patients with acute calcium pyrophosphate crystal arthritis demonstrate double the risk for fractures vs. matched comparators, according to data presented at ACR Convergence 2023.

People who work lower-paid, manual-labor jobs are more likely to discontinue employment in the first 5 years after an early inflammatory arthritis diagnosis, vs. those who work in managerial or professional capacities, according to data.

SAN DIEGO — Premature all-cause mortality in gout remains elevated vs. individuals without gout in the United States and United Kingdom, with worse rates reported among women, according to data presented at ACR Convergence 2023.